Department of Urology, Penang General Hospital, Penang, Malaysia.
Urology Unit, Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia.
Andrologia. 2022 Oct;54(9):e14518. doi: 10.1111/and.14518. Epub 2022 Jul 1.
Low-intensity shockwave therapy (LiSWT) has emerged as a promising non-invasive treatment modality for erectile dysfunction (ED) yet the well-designed randomized clinical trials are still lacking to prove its claimed benefits. A randomized, prospective, double-blinded sham-controlled study was conducted to evaluate the effectiveness and safety profile of short course LiSWT on vasculogenic ED patients. The International Index of Erectile Function-5 (IIEF-5) and Erection Hardness Score (EHS) questionnaires were used for evaluation. Patients underwent weekly sessions for 4 weeks and were re-assessed at 1, 3 and 6 months post therapy. Fifty one patients were recruited and randomized into sham and treatment arms. The mean IIEF-5 scores were significantly improved in the treatment arm compared to worsening of scores in the sham arm after 1 month (14.1 vs. 9.3 p < 0.001), 3 months (14.9 vs. 8.6, p < 0.001) and 6 months (14.2 vs. 7.9, p < 0.001) post treatment. A significant improvement of EHS was demonstrated at 1 month (2.4 vs. 1.8, p = 0.001, 3 months 2.7 vs. 1.7, p < 0.001) and 6 months (2.7 vs. 1.6, p < 0.001) in the treatment arm compared to sham arm. The success rate based on IIEF score increment more than five points was 26% in treatment arm and 0% in sham arm. Improvement in EHS score ≥3 in the treatment versus sham arm was 63% and 4%, respectively. There was no adverse effect reported. This 4-week LiSWT protocol reflects better treatment compliance, and it prevents further deterioration of erectile function among this cohort of patients. This study proves that LiSWT is a well-tolerated treatment with modest improvements in erectile function and hardness, among patients with vasculogenic ED.
低强度冲击波疗法 (LiSWT) 已成为治疗勃起功能障碍 (ED) 的一种有前途的非侵入性治疗方法,但仍缺乏精心设计的随机临床试验来证明其声称的益处。一项随机、前瞻性、双盲假对照研究评估了短期 LiSWT 对血管性 ED 患者的有效性和安全性。使用国际勃起功能指数-5 (IIEF-5) 和勃起硬度评分 (EHS) 问卷进行评估。患者每周接受一次治疗,共 4 周,并在治疗后 1、3 和 6 个月进行重新评估。共招募了 51 名患者,并随机分为假治疗组和治疗组。与假治疗组相比,治疗组的 IIEF-5 评分在治疗后 1 个月(14.1 对 9.3,p < 0.001)、3 个月(14.9 对 8.6,p < 0.001)和 6 个月(14.2 对 7.9,p < 0.001)时显著改善。EHS 也显示出显著改善,在治疗后 1 个月(2.4 对 1.8,p = 0.001)、3 个月(2.7 对 1.7,p < 0.001)和 6 个月(2.7 对 1.6,p < 0.001)时改善。根据 IIEF 评分增加 5 分以上的成功率,治疗组为 26%,假治疗组为 0%。EHS 评分改善≥3 的治疗组与假治疗组分别为 63%和 4%。未报告不良反应。这种 4 周 LiSWT 方案反映了更好的治疗依从性,并防止了该队列患者勃起功能的进一步恶化。这项研究证明,LiSWT 是一种耐受良好的治疗方法,可适度改善血管性 ED 患者的勃起功能和硬度。